Table 3.
Clinical variables in UME with and without anatomical improvement.
| Clinical variables at baseline | Total | No improvement | Improvement1 | P-value2 | |
|---|---|---|---|---|---|
| Total (eyes/patients) | 60/60 | 38/38 | 22/22 | ||
| Clinical imputs | |||||
| Age (years, mean ± SD) | 51.1 ± 15.1 | 54 ± 14.7 | 46.1 ± 14.8 | 0.063 | |
| Female, n (%) | 35 (58.3) | 24 (63.2) | 11 (50) | 0.319 | |
| Evolution time (months, mean ± SD) | 17.3 ± 31.5 | 12.5 ± 22.49 | 25.7 ± 42.2 | 0.357 | |
| Bilateral, n (%) | 23 (38.3) | 14 (36.8) | 9 (40.9) | 0.755 | |
| ACC (SUN) > 0.5+, n (%) | 29 (48.3) | 17 (44.7) | 12 (54.5) | 0.464 | |
| Keratic precipitates, n (%) | Fines | 10 (16.9) | 7 (18.9) | 3 (13.6) | 0.725 |
| Granulomatous | 6 (10.2) | 3 (8.1) | 3 (13.6) | ||
| Vitreous haze (NEI) > 0.5+, n (%) | 29 (48.3) | 20 (52.6) | 9 (40.9) | 0.381 | |
| Chorioretinal lesions (any), (%) | 15 (25) | 12 (31.6) | 3 (13.6) | 0.122 | |
| Anterior uveitis (SUN), n (%) | 16 (26.7) | 9 (23.7) | 7 (31.8) | 0.492 | |
| Unclassifiable uveitis, n (%) | 7 (20.6) | 5 (23.8) | 2 (15.4) | 0.654 | |
| Ocular comorbidities, n (%) | Cataract | 16 (26.7) | 8 (21.1) | 8 (36.4) | 0.196 |
| Glaucoma | 11 (18.3) | 7 (18.4) | 4 (18.2) | 0.982 | |
| Treatments for UME, n (%) | None | 4 (6.9) | 4 (10.8) | 0 (0) | |
| Local only | 14 (23.3) | 10 (27) | 4 (19) | 0.191 | |
| Systemic | 40 (66.7) | 23 (62.2) | 17 (81) | ||
| SD-OCT imputs | |||||
| Macular volume (mm3, mean ± SD) Thickened vitreo-macular interface, n (%) |
11.9 ± 1.9 18(30) |
11.5 ± 1.3 14 (36.8) |
12.6 ± 2.6 4 (18.2) |
0.063 0.129 |
|
| Unaltered ellipsoid layer, n (%) | 35 (58.3) | 25 (65.8) | 10 (45.5) | 0.124 | |
| Significant Tractional component, n (%) | 7 (11.7) | 7 (18.4) | 0 (0) | 0.032 | |
| UME cystoid component, n (%) | 47 (78.3) | 29 (76.3) | 18 (81.8) | 0.618 | |
| Diameter of major cyst (µm, mean ± SD) | 330.1 ± 475.5 | 266.8 ± 208.8 | 433.5 ± 723.2 | 0.706 | |
| UME diffuse component, n (%) | 14 (23.3) | 11 (28.9) | 3 (13.6) | 0.177 | |
| SRF transverse extent (µm, mean ± SD) | 363.1 ± 520.2 | 169 ± 271.6 | 621.9 ± 665.8 | 0.021 | |
| Choroidal thickness (µm, mean ± SD) | 272.8 ± 97.7 | 258.5 ± 80.6 | 297.4 ± 119.9 | 0.137 | |
| Immune imputs | |||||
| Tregs (% CD3+ CD4+ PoxP3+) | 4.2 ± 2.6 | 4.0 ± 2.3 | 4.9 ± 2.9 | 0.153 | |
| TNFα (pg/mL) | 8.9 ± 8.2 | 10.1 ± 9.3 | 7.1 ± 5.9 | 0.136 | |
| IL-1β (pg/mL) | 0.7 ± 1.4 | 1.0 ± 1.7 | 0.3 ± 0.3 | 0.075 | |
| IL-6 (pg/mL) | 4.7 ± 11.9 | 6.2 ± 14.2 | 2.3 ± 6.7 | 0.064 | |
| IL-8 (pg/mL) | 12.9 ± 18.5 | 14.7 ± 21.8 | 10.0 ± 11.1 | 0.281 | |
| IL-10 (pg/mL) | 1.5 ± 5.4 | 1.1 ± 2.4 | 2.1 ± 8.3 | 0.281 | |
| IL-17 (pg/mL) | 12.7 ± 25.4 | 9.5 ± 14.3 | 17.9 ± 36.9 | 0.589 | |
| MCP-1 (pg/mL) | 645.6 ± 396.3 | 656.3 ± 410.8 | 628.4 ± 381.0 | 0.822 | |
| VEGF (pg/mL) | 263.8 ± 195.8 | 282.5 ± 178.8 | 233.6 ± 221.7 | 0.127 |
1Improvement, defined as per decrease ≥20% or reach <300 µm in central subfield thickness at 6 months and maintained through month 12.
2Chi-square or Fisher (categorical), Mann-Whitney (continuous).
ACC, anterior chamber cells; SUN standardization of uveitis nomenclature; NEI, National Eye Institute scale; UME, uveitic macular edema; SD-OCT, spectral-domain optical coherence tomography; SRF, subretinal fluid; TNF, tumor necrosis factor; IL, interleukin; MCP, monocyte chemoattractant protein; VEGF, vascular endothelial growth factor; Tregs, regulatory T cells.